153 related articles for article (PubMed ID: 16336094)
1. Molecularly targeted therapy in renal cell carcinoma.
Rathmell WK; Wright TM; Rini BI
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1031-40. PubMed ID: 16336094
[TBL] [Abstract][Full Text] [Related]
2. [Molecular targeted therapy for renal cell carcinoma].
Kakehi Y
Rinsho Ketsueki; 2008 Aug; 49(8):622-5. PubMed ID: 18800611
[No Abstract] [Full Text] [Related]
3. VEGF-targeted therapy in metastatic renal cell carcinoma.
Rini BI
Oncologist; 2005 Mar; 10(3):191-7. PubMed ID: 15793222
[TBL] [Abstract][Full Text] [Related]
4. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
5. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
[TBL] [Abstract][Full Text] [Related]
6. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
7. [Molecular tumor board-renal cell carcinoma].
Grünwald V; Doehn C; Goebell PJ
Urologe A; 2019 Jul; 58(7):768-773. PubMed ID: 31175376
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to targeted therapy in renal cell carcinoma.
Eisengart LJ; MacVicar GR; Yang XJ
Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
[TBL] [Abstract][Full Text] [Related]
9. Lord of the rings: a promising novel treatment for renal cell carcinoma?
Johansson M
Eur Urol; 2011 May; 59(5):745-6. PubMed ID: 21276657
[No Abstract] [Full Text] [Related]
10. Anti-angiogenic therapy in renal cell carcinoma.
Sharma SG; Nanda S; Longo S
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):77-83. PubMed ID: 19601920
[TBL] [Abstract][Full Text] [Related]
11. [Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway].
Kuefer R; Autenrieth M; Herkommer K; Blum P; Merseburger A; Hofer M; Rinnab L; Gschwend J; Ringhoffer M
Urologe A; 2006 Mar; 45(3):328, 330-5. PubMed ID: 16465522
[TBL] [Abstract][Full Text] [Related]
12. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
13. Renal cell carcinoma.
Rini BI; Rathmell WK; Godley P
Curr Opin Oncol; 2008 May; 20(3):300-6. PubMed ID: 18391630
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Gollob JA
Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.
Karashima T; Inoue K; Fukata S; Iiyama T; Kurabayashi A; Kawada C; Shuin T
Int J Oncol; 2007 Apr; 30(4):937-45. PubMed ID: 17332933
[TBL] [Abstract][Full Text] [Related]
16. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.
Sutphin PD; Chan DA; Li JM; Turcotte S; Krieg AJ; Giaccia AJ
Cancer Res; 2007 Jun; 67(12):5896-905. PubMed ID: 17575159
[TBL] [Abstract][Full Text] [Related]
17. Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
Figlin RA; Alvin H; Meinhardt CL
Urologe A; 2004 Sep; 43 Suppl 3():S144-5. PubMed ID: 15179554
[No Abstract] [Full Text] [Related]
18. Renal-cell carcinoma--molecular pathways and therapies.
Brugarolas J
N Engl J Med; 2007 Jan; 356(2):185-7. PubMed ID: 17215538
[No Abstract] [Full Text] [Related]
19. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
20. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
Hutson TE; Sonpavde G; Galsky MD
Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S31-9. PubMed ID: 17239282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]